Revenue
No reported data
Kailera Therapeutics, Inc. (KLRA)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | $109.1M | $7.0M |
| Operating income | −$158.3M | −$230.4M |
| EBITDAderived | −$158.0M | −$230.4M |
| Net income | −$149.0M | −$219.7M |
| Diluted EPSper diluted share | -$949.00 | -$219,713.00 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 20, 2026Form 4 | RTW INVESTMENTS, LP +1TenPercentOwner | BuyCommon Stock · indirect | 500.0K | $16.00 | $8.00M | 10.78M |
| Apr 20, 2026Form 4 | BCPE Perseus Investor, LP +4TenPercentOwner | BuyCommon Stock · indirect | 8.40M | $16.00 | $134.38M | 26.26M |
| Apr 20, 2026Form 4 | Koppel AdamDirector,TenPercentOwner | BuyCommon Stock · indirect | 1.56M | $16.00 | $25.00M | 22.58M |
| Apr 20, 2026Form 4 | BCLS Fund IV Investments GP, LLC +4TenPercentOwner | BuyCommon Stock · indirect | 1.56M | $16.00 | $25.00M | 22.58M |
| Apr 20, 2026Form 4 | Kaplan Andrew T.Director,TenPercentOwner | BuyCommon Stock · indirect | 8.40M | $16.00 | $134.38M | 26.26M |